Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06431594 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Solid Tumors, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT06431594: Recruiting Phase 1 study of Neoplasms and Solid Tumors, sponsored by GlaxoSmithKline.
NCT06431594 is a Phase 1 study of Neoplasms and Solid Tumors that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 385 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06431594, a Phase 1 study of Neoplasms and Solid Tumors, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.
Conditions Studied
Interventions
- DRUG GSK5733584
Study Locations (20)
Other
- GSK Investigational Site - Cipoletti Rio Negro
- GSK Investigational Site - Ciudad de Buenos Aires
- GSK Investigational Site - Rosario
- GSK Investigational Site - Leuven
- GSK Investigational Site - Helsinki
- GSK Investigational Site - Helsinki
Massachusetts
- GSK Investigational Site - Boston
- GSK Investigational Site - Boston
Michigan
- GSK Investigational Site - Detroit
- GSK Investigational Site - Grand Rapids
New South Wales
- GSK Investigational Site - Blacktown
- GSK Investigational Site - Macquarie University
Ontario
- GSK Investigational Site - Ottawa
- GSK Investigational Site - Toronto
Florida
- GSK Investigational Site - Lake Mary
Kansas
- GSK Investigational Site - Fairway
Tennessee
- GSK Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2027-09-20 |
| Phase | Phase 1 |
What NCT06431594 shows while recruiting
NCT06431594 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5733584 is the first listed.
NCT06431594 names 20 study sites across 11 states, led by Other, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06431594 about?
NCT06431594 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors". The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.
What is the current status of trial NCT06431594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 385 participants. The study started on 2024-07-02. Estimated completion is 2027-09-20.
What conditions does trial NCT06431594 study?
This clinical trial studies the following conditions: Neoplasms, Solid Tumors.
What interventions are being tested in trial NCT06431594?
The interventions under investigation include: GSK5733584 (DRUG).
Who is sponsoring clinical trial NCT06431594?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06431594 being conducted?
This trial has 20 study locations across Florida, Kansas, Massachusetts, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06431594's enrollment target sits among peer trials
385 28th of 158 higher than 131 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06226883 · 385 participants · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- NCT06290063 · 385 participants · Phase 2
Cannabidiol and Older Adult Cannabis Users
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI